Navigation Links
Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
Date:1/29/2008

TORONTO, Jan. 29 /PRNewswire/ - Viventia Biotech Inc., a privately held biopharmaceutical company advancing a portfolio of novel antibody therapeutics focused on cancer, announced today it intends to explore strategic alternatives to further advance and realize value from its pipeline of therapeutic antibodies, its antibody discovery platform and its antibody manufacturing capabilities. The Company will consider potential strategic opportunities including, but not limited to, the sale or merger of the Company with another entity, and has retained HSBC to act as advisors in this process.

The Company also provided an update on the clinical development programs for Proxinium(TM) (Phase 3), Vicinium(TM) (Phase 2) and VB6-845 (Phase 1). Proxinium(TM) is undergoing a global pivotal Phase 3 trial (the 'TARGET' trial) in approximately 300 patients with advanced head and neck cancer. Viventia recently completed an interim efficacy assessment on the study's primary endpoint of median survival. These preliminary results demonstrated a clear survival advantage in the Proxinium(TM) arm.

"We have successfully advanced three antibody programs into clinical trials, and are about twelve months from expected final efficacy data for our pivotal Phase 3 TARGET trial of Proxinium(TM). We believe that our recently performed interim efficacy analysis of survival data from TARGET strongly supports the future prospects for this drug. In addition to our clinical programs, we have generated a broad pipeline from our antibody discovery platform, which has yielded a number of compelling novel targets, including several that have expression profiles consistent with cancer stem cells, an exciting new area of cancer research," said Dr. Nick Glover, President and CEO of Viventia Biotech. "We believe it is important to explore all options to ensure adequate resources are available for the advancement of our products through to commercialization and to further recognize the value
'/>"/>

SOURCE Viventia Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a ... technical service business units, Whitehouse Laboratories is pleased to announce that it has begun ... Container Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... Asia-Pacific / Japan (Q2 2015: +14% CER ... 2015 on high-single-digit growth in China , as well as ... . Europe / Middle East ... of sales) showed gains in Germany , Turkey ... 2015: +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, ...
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
Breaking Biology Technology:Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... Aug. 31 A high-tech device that expands the visual ... test in a walking simulator, according to scientists at Schepens ... issue of Investigative Ophthalmology and Visual Science. The study ... tiny camera, pocket-sized computer and a transparent computer display on ...
... , , ... or the "Company"), a development-stage company focused on the discovery, ... acute care antibiotic-resistant infections, today announced that one of its ... unique compounds demonstrating efficacy in the treatment of infection in ...
... , , , FREDERICK, Md., Aug. ... Scientist Magazine,s 2009 Top 30 Best Places to Work ... those companies with the most positive work environment, dedicated management, and innovative ... Places to Work Industry award for biotech and pharmaceutical companies. ...
Cached Biology Technology:New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 2New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 3Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria 2Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria 3SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies 2
(Date:7/31/2015)... 2015 La 10e Conférence internationale sur ... par le BGI du 22 au 25 octobre ... Chine. La conférence célèbre son 10e ... l,ICG est devenue l,une des réunions annuelles mondiales ... et c,est aussi la plus dynamique, la plus ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... (MGH) researchers have developed a new type of miniature ... expand the application of minimally invasive diagnostic and therapeutic ... the team from the Wellman Center for Photomedicine at ... its use in a mouse model. , ...
... 4 cases of botulism following cosmetic injections to the ... unlicensed preparation that resulted in toxin levels up to ... a report in the November 22/29 issue of JAMA. ... by the toxins of the spore-forming bacterium Clostridium botulinum ...
... collaborating institutions report in this week's Science a ... 2.8 kilometers below Earth's surface. Think that's weird? ... water molecules to useable energy. , The ... the three-dimensional shell that encompasses all planetary life. ...
Cached Biology News:Three-dimensional, miniature endoscope opens new diagnostic possibilities 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3
...
... Purification Kit is designed for isolating DNA from ... protocol can be completed in less than one ... larger amounts of DNA. The purified DNA can ... Southern blotting. The MasterPure Kit was designed for ...
Caspase Activity Detector, SR-VAD-FMK Kit , 100 tests Consult technical datasheet for details....
HistoScan AP Universal Goat Kit...
Biology Products: